The goal of the present study was to evaluate a novel prospective influenza vaccination strategy for patients with plasma cell disorders. Fifty-one patients were treated with a 2-dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated and led to very high rates of seroprotection against influenza. Background: Patients with multiple myeloma (MM) and other plasma cell disorders are highly susceptible to influenza infections, which are major causes of morbidity in this population, despite the routine administration of a seasonal influenza vaccination. Existing data are limited by small and retrospective studies, which suggest poor seroprotection rates of < 20% after standard influenza vaccination in patients with MM. Patients and Methods: Patients with plasma cell dyscrasia (n ¼ 51) were treated with a 2-dose series of high-dose inactivated trivalent influenza vaccine during the 2014 to 2015 influenza season. Laboratory-confirmed influenza infections were identified through seasonal surveillance, sera were collected for influenza hemagglutination antibody inhibition (HAI) titer assays, and logistic regression models were used to identify the clinical correlates to the HAI serologic responses. Results: Influenza vaccine was well tolerated, without any vaccine-related grade 2 adverse events. Only 3 patients (6%) experienced laboratoryconfirmed influenza. The rates of HAI seroprotection against all 3 vaccine strains (A/California/7/2009 [H1N1] pdm09-like virus; A/Texas/50/2012 [H3N2]-like virus; and a B/Massachusetts/2/2012-like virus) increased from 4% at baseline to 49% and 65% after 1 and 2 doses, respectively. The risk factors associated with a lower likelihood of HAI serologic response included plasma cell disorder requiring therapy, less than a partial response found on disease response assessment, and active conventional chemotherapy. Alternatively, active therapy with an immunomodulatory drug alone or with a proteasome inhibitor was associated with a greater likelihood of an HAI serologic response. Conclusion: These data have demonstrated that, in contrast to the historically poor results with standard influenza vaccination, this novel high-dose booster vaccination strategy leads to high rates of seroprotection. Randomized controlled studies are needed to compare this novel strategy to the standard vaccination strategy.
Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder (PCD), marked by neoplastic plasma cells in bone marrow that secrete monoclonal immunoglobulins. 1 Infections are a significant cause of morbidity and a leading cause of death for patients with MM. 2 Influenza is a major cause of morbidity and in the United
States is responsible for > 40,000 deaths annually. 3 Despite the routine administration of a seasonal influenza vaccination to patients with MM, the risk of influenza infection remains high. A Swedish study of > 9000 myeloma patients demonstrated that myeloma was associated with a 10-fold increased risk of viral infections, including a 6.1-fold risk of influenza, relative to healthy controls. 4 Patients with MM have multiple factors that contribute to immunosuppression, including suppression of normal uninvolved immunoglobulins and alteration in T-cell immunity. 5, 6 Anticancer therapies can further affect the immune system, and chemotherapy has been associated with diminished protection from influenza vaccination. 7, 8 Finally, immunity in patients with PCDs is also affected by the age-related decline in immune function. The US Advisory Committee on Immunization Practices has recommended that all adults aged 50 years and immunocompromised individuals, such as those with MM, receive a single annual dose of inactivated influenza vaccine. 9 Inactivated influenza vaccination is associated with a robust primary serologic antibody response against hemagglutinin surface protein of each viral subtype within the vaccine, which can be measured by the hemagglutination antibody inhibition (HAI) titer levels. Seroconversion refers to a fourfold or greater increase in HAI titers, and seroprotection refers to an HAI titer level of 1:40. HAI seroprotection corresponds to an estimated 50% clinical protection from influenza infections according to the results of studies of young, healthy adults. 10, 11 HAI titers are the most widely accepted serologic correlates and form the basis for the approval of new influenza vaccines. 12 The existing data on influenza vaccine responses in MM patients are limited but suggest that low HAI titers with seroprotection rates of < 20% after standard influenza vaccination. 8, [13] [14] [15] One potential approach to enhancing the immune efficacy of a vaccine is the administration of a booster dose. Two studies previously investigated the benefit of a 4-week booster dose of a standard-dose influenza vaccine in MM patients. Ljungman et al 15 randomly assigned a mix of patients with all hematologic malignancies (including 10 with MM and 4 with Waldenström macroglobulinemia) to vaccination with 1 versus 2 doses of influenza vaccine and found no overall increase in serologic protection in the cohort receiving 2 vaccines. However, their study included patients with diverse hematologic malignancies that differed in their capacity to respond to vaccines. Hahn et al 14 reported the findings from a retrospective analysis of 48 MM patients during the 2013 to 2014 influenza season at their institution. Seroprotection after 1 vaccine was detected in only 7 patients (14%). Of the remaining 41 patients, 24 received a second vaccine, and 33% of these patients achieved seroprotection. Because of the retrospective nature of the study, the effects on influenza infection were not systematically evaluated. An unmet need remains for prospective data evaluating the clinical and serologic efficacy of the influenza vaccination specifically in PCD patients because the existing data suggest that only a few patients respond to the current vaccination strategy. One potential approach to enhance vaccine efficacy is to administer a higher dose of antigen. Based on studies reporting increased serologic protection, Fluzone High-Dose inactivated influenza vaccine (Sanofi Pasteur, Swiftwater, PA) was approved in the United States for adults aged 65 years (60 mg HAI vs. 15 mg standard dose). Safdar et al 16 observed an improvement in vaccineinduced HAI titer responses by increasing the hemagglutinin antigen level in a dose-dependent fashion of 135 mg without increased toxicity. Previous studies have not specifically evaluated a booster strategy with a high-dose influenza vaccine for MM patients. Therefore, we designed a novel influenza strategy for MM patients combining the use of a high-dose inactivated influenza vaccine and a 2-dose series in the present study.
Patients and Methods

Clinical Trial Design
We evaluated a novel influenza vaccine strategy in the SHIVERING trial (study of high-dose influenza vaccine efficacy by repeated dosing in gammopathy patients) during the 2014 to 2015 influenza season. This pilot clinical trial was conducted at a single, US academic hospital (Yale Smilow Cancer Hospital). The eligibility criteria allowed inclusion of any patient with a diagnosis of MM or another PCD without any known contraindication to trivalent inactivated influenza vaccine. All participants received the study intervention of 2 doses of trivalent Fluzone High-Dose influenza vaccination 30 days apart, regardless of age. The participants were stratified into 2 broad cohorts: those with PCD requiring therapy and those with asymptomatic gammopathy. The present analysis focused on the changes in the HAI titer serologic response rates. Other endpoints included safety and the laboratory-confirmed influenza infection rates.
Study Oversight
The trial was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and appropriate regulatory requirements. The local ethics committees or institutional review boards approved the protocol. All patients provided written informed consent. The trial was registered before patient enrollment at Clinicaltrials.gov (ClinicalTrials.gov identifier, NCT02267733). 
Study Influenza Vaccine
HAI Titer Measurements
HAI assays were performed using the following standardized protocol. 17 In brief, sera were treated with a receptor destroying each influenza virus strain. The serum virus samples were then incubated at room temperature for 30 minutes to allow any HA-specific antibodies present in the serum to neutralize the influenza virus. To each well, a 0.5% suspension of red blood cells was then added. The assay was then incubated on ice until the red blood cells in the buffer control sample formed a button and had agglutinated in the noneserum-containing control well. The HI titer is defined as the reciprocal of the highest dilution of serum that inhibits red blood cell agglutination. As defined previously, 18 seroprotection to the influenza virus vaccine is based on achieving an antibody titer of 1:40, and seroconversion to the influenza virus vaccine is based on a fourfold increase in antibody titers.
Influenza Infection Surveillance
All study participants underwent active influenza surveillance from enrollment until the end of the influenza season, May 31, 2015. Possible influenza infection was considered based on either (1) a respiratory illness defined as the occurrence of 1 of sneezing, nasal congestion or rhinorrhea, sore throat, cough, sputum production, wheezing, or difficulty breathing; or (2) a protocol-defined influenza-like illness using the current Common Terminology Criteria for Adverse Events, version 4.0, defined as a constellation of symptoms, including dry cough, temperature > 38 C, chills, body aches, malaise, and loss of appetite. If a patient met the criteria for possible influenza infection, the staff members at the study site attempted to collect a nasopharyngeal swab within 5 days after the onset of the illness. Laboratory confirmation of influenza in the nasopharyngeal swabs was considered by a positive result with direct fluorescent antibody or polymerase chain reaction testing.
Statistical Analysis
The patient characteristics were summarized as frequencies and percentages for categorical variables and the median and range for continuous variables. The McNemar test was used to compare the changes in the seroprotection rate from baseline to after the first vaccination and after second vaccination and the changes in the seroconversion rate from after the first vaccination to after the second vaccination. Generalized Estimating Equations were used to correlate the binary outcomes to assess the effect of individual risk factors on seroprotection and seroconversion. A secondary outcome was the comparison of the rate of laboratory-confirmed influenza in this cohort to the average expected annual infection rate (20%) using Fisher's exact test. The 95% confidence interval (CI) was calculated. For all statistical tests, the significance level was set at P < .05, 2 sided, and all analyses were performed using SAS, version 9.4.2 (SAS Institute, Cary, NC).
Results
A total of 51 patients were enrolled, and all patients received both doses of the Fluzone High-Dose influenza vaccine. Of the 51 patients, 49 had a diagnosis of MM and 2 of Waldenström macroglobulinemia. Also, 41 patients had disease-requiring therapy and 10 had either monoclonal gammopathy of undetermined significance (MGUS) or asymptomatic disease. The median age was 65 years; additional baseline patient characteristics are summarized in Table 1 .
Safety
No patients experienced grade 2 adverse events attributed to the vaccine. The most common side effects were mild local soreness and redness around the site of injection, muscle aches, and general malaise.
HAI Titer Response Rates
The rates of seroprotection significantly improved after 1 and 2 doses of the Fluzone High-Dose vaccine for all 3 influenza vaccine strains compared with baseline ( Figure 1A and Supplemental Table 1 [available in the online version]; P < .0001, for all). Oral cyclophosphamide, n ¼ 7; 5-fluorouracil and oxaliplatin for concurrent colorectal cancer, n ¼ 1.
Response With 2-doses of High-dose Influenza Vaccine in Plasma Cell Disorders
Seroprotection against influenza B improved significantly after the second dose (57%-84%; P < .0001); however, no significant increase was observed against the individual H1N1 or H3N2 strains. The total seroprotection rate (seroprotection against all 3 vaccine influenza strains) increased from 4% at baseline to 47% after the initial dose (P < .001) and 65% after the second dose (P < .01).
The rates of seroconversion against H3N2, H1N1, influenza B, and all 3 combined strains after the initial dose were 69% (35 of 51), 73% (37 of 51), 67% (34 of 51), and 39% (20 of 51), respectively. Seroconversion against influenza B improved significantly after the second dose (67%-96%; P < .001) and seroconversion against all 3 strains increased from 39% to 55% after the second vaccination (P ¼ .02; Figure 1B 
Clinical Correlates of Serologic Response
We used Generalized Estimating Equations logistic regression modeling 19 to identify the potential variables associated with total seroprotection ( Figure 2A ) and seroconversion ( Figure 2B ). Seven variables were significantly associated with the overall odds of seroprotection. Receiving both doses of study vaccine, active treatment with intravenous immunoglobulin (IVIG) and a diagnosis of influenza infection in the previous influenza season were associated with greater odds of seroprotection. In contrast, the following 4 variables were associated with lower odds of seroprotection: a diagnosis of PCD requiring therapy (vs. asymptomatic disease or MGUS), active therapy with conventional chemotherapy, suppression of uninvolved immunoglobulins, and a laboratory-confirmed diagnosis of a viral respiratory infection other than influenza during the study period. A fifth variable of a disease response status of less than a partial response at study entry was identified as showing a trend toward a lower likelihood of seroprotection (P ¼ .07). Figure 3 summarizes all 5 unfavorable risk factors associated with a lower likelihood of achieving total seroprotection. Both doses of study vaccine significantly improved the likelihood of total seroprotection compared with baseline, with an odds ratio (OR) of 21.78 (95% CI, 5.35-88.57; P < .001) after the initial dose and OR of 44.90 (95% CI, 10.59-190.44; P < .001) after the second dose. Additionally, the second dose significantly boosted the total seroprotection relative to the initial dose, with an OR of 2.06 (95% CI, 1.20-3.55; P ¼ .009). These changes were still significant after controlling for all other variables, including age, sex, a diagnosis of PCD requiring therapy, active treatment with IVIG, suppression of uninvolved immunoglobulins, a diagnosis of influenza 1 year before study entry, and a diagnosis of other respiratory viral infections during the study, with an adjusted OR of 2.61 (95% CI, 1.35-5.07; P ¼ .005) from the first to the second dose of vaccine. Older age was associated with a significantly lower likelihood of achieving seroconversion against all 3 vaccine strains. In contrast, active therapy with an immunomodulatory drug (IMID), with or without combination with a proteasome inhibitor, was associated with a greater likelihood of achieving seroconversion against all 3 vaccine strains. The second dose of vaccine significantly boosted seroconversion against all 3 influenza strains compared with the initial dose, with an OR of 1.89 (95% CI, 1.12-3.17; P ¼ .02). This change retained its significance after we controlled for age, sex, a diagnosis of PCD requiring therapy, and active treatment with a combination proteasome inhibitor plus IMID. The adjusted OR was 2.19 (95% CI, 1.17-4.08; P ¼ .01), indicating the odds of overall conversion had doubled after a second vaccine dose. In adjusted analysis, older age remained a significant predictor of a lower likelihood of seroconversion independent of vaccination (OR per 10 years' increase in age, 0.38; 95% CI, 0.20-0.72; P ¼ .003).
Laboratory-confirmed Influenza Infections
Only 3 of the 51 total patients enrolled developed laboratoryconfirmed influenza infections, and their individual characteristics are summarized in Supplemental Table 3 (available in the online version). The infection rate was 5.9% (95% CI, 1.2%-16.2%). The infection rate was significantly lower than the expected 20% infection rate based on the Centers for Disease Control and Prevention estimate (P ¼ .01; Supplemental Figure 1 ; available in the online version).
Discussion
The results of the present prospective pilot clinical trial suggest both the safety and the efficacy of a 2-dose series of trivalent Fluzone High-Dose influenza vaccine for MM patients. This influenza vaccine strategy was well tolerated without any unexpected or vaccine-related serious adverse events. The observed rates of HAI titer seroprotection and seroconversion against all 3 vaccine influenza strains significantly improved after 2 doses compared with after 1 dose. To the best of our knowledge, the present study is the first to demonstrate that the generation of protective antibody titers after influenza vaccination is possible in most MM patients. Furthermore, improved clinical benefit was suggested by the laboratoryconfirmed influenza infection rate of 6% compared with an expected rate of 20%.
Total seroprotection after 1 dose of high-dose vaccine reached 47% and increased significantly again to 65% after a second dose. These data compare favorably with those from previous studies suggesting seroprotection rates of < 20% with a single standard vaccine 8 and 33% with 2 doses of standard vaccine. 14 The rates of seroconversion also improved significantly to 39% after both the initial dose and to 55% after the second dose. The rates of improvement for both seroprotection and seroconversion after the second dose compared with the initial dose were largely driven by HAI titers against influenza B. It is unclear why the HAI titers after a second dose were more robust for influenza B and whether this vaccination strategy is particularly important for an influenza B-specific response.
In the present study, we identified 5 clinical risk factors that are associated with an overall lower likelihood of achieving total seroconversion: (1) PCD requiring therapy (vs. asymptomatic disease or MGUS), (2) suppression of uninvolved immunoglobulins, (3) active treatment with conventional chemotherapy, (4) a disease response status of less than a partial response, and (5) a diagnosis of respiratory infections other than influenza during the influenza season. Although seroprotection improved for all study patients as a whole after 2 doses of the high-dose influenza vaccine, the patients with 3 of these unfavorable risk factors seemed to experience the greatest benefit from the second dose. Our findings support the idea that infectious risk generally increases with a higher tumor burden in MM. Studies have demonstrated a particularly high risk of infection in the first month of diagnosis that improves with initial therapy; however, the infectious risk again worsens with later stages of disease progression. 20 Our data also identified active treatment of conventional chemotherapy as an unfavorable risk factor, which was also noted previously in general oncology patients. 21 Additionally, patients with concurrent viral respiratory infections had a lower risk of seroprotection, suggesting that a subgroup of MM patients might have a state of increased overall infectious risk. Patients with a history of documented influenza infection in the preceding year had greater rates of seroprotection, indicating that understanding the immune response to natural infection might provide a template for improving vaccine strategies. Similarly, IVIG administration might strains. The underlying mechanism requires further study but might be related to improved disease control or an immune benefit driven by IMIDs, as suggested previously. 22 We did not observe an adverse effect of corticosteroid therapy on the serologic responses. We chose to use formal surveillance to carefully determine the number of laboratory-confirmed influenza infections as an endpoint in the present study. Such clinical endpoints as Response With 2-doses of High-dose Influenza Vaccine in Plasma Cell Disorders laboratory-confirmed influenza infection rates are lacking from most vaccine studies involving MM patients. Similarly, correlations between the HAI titer response rates and protection from clinical influenza infections in MM patients are unknown. However, our findings suggest concordance between protective HAI titers and protection from infection. For example, 1 patient was infected with influenza B and lacked seroprotective HAI titers to influenza B but had protective titers to the other strains. The other 2 patients were infected with H3N2, and although both had achieved seroprotective HAI titers to H3N2, circulating H3N2 had been very poorly matched during the 2014 to 2015 influenza season (Centers for Disease Control and Prevention estimated that > 80% had drifted from the vaccine strain 23 ).
Despite these encouraging results, we recognize the limitations of a relatively small single-arm pilot study. Larger sample sizes are needed for detailed analysis of the risk factors predictive of a poor response. Furthermore, a nonrandomized trial is limited to historical comparisons, which can be particularly challenging with influenza, given the high season-to-season variability. Nonetheless, the seroprotection rates observed in the present study, to the best of our knowledge, have not been achieved with any previous influenza vaccination strategy in MM. As such, we are currently conducting a randomized, double-blind, clinical trial comparing this novel 2-dose series of Fluzone High Dose influenza vaccine to a single age-based standard-of-care vaccination. Patients in the present study identified as having favorable risk factors (those without hypogammaglobulinemia, asymptomatic patients, and those with more than a partial response to therapy) displayed high serologic responses after a single high-dose vaccination; thus, the added benefit of a 2-dose series in these patients was not demonstrated. In contrast, the subsets of patients with the high-risk features we identified achieved suboptimal seroprotection rates using this approach, and newer vaccine strategies should be explored for this cohort. The use of clinically relevant endpoints for MM patients (eg, influenza infection rates, influenza-associated hospitalizations, and mortality) will be crucial in better understanding the true burden of influenza in this patient population.
Clinical Practice Points
PCDs are associated with immunoparesis, frequently involving hypogammaglobulinemia and other multifactorial defects of immune function. Infections are a major source of both morbidity and mortality in patients with PCDs. Patients with PCDs are highly susceptible to influenza infections, despite widespread standard vaccination practices. The results of the present novel, prospective trial suggest that 2 doses of high-dose influenza vaccine separated by 30 days is associated with high rates of seroprotection in patients with PCDs; however, larger, randomized trials with clinical endpoints are needed to confirm the efficacy of this novel vaccination strategy. Supplemental Figure 1 Laboratory-confirmed Influenza Infection Rate Supplemental 
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